Antibody-drug conjugates (ADCs) are complex biopharmaceuticals that require rigorous control across their entire development life cycle – from early cell bank characterization through to final batch release. Join our webinar for a clear, end-to-end look at the steps that shape ADC quality, safety and regulatory readiness.
Experts, Drs. Richard Adair and Greg Adams, will break down the key regulatory expectations and analytical requirements at each stage of ADC development. You will see how best-practice analytical strategies and advanced technologies strengthen control of critical quality attributes, reduce development risk and support efficient, compliant progression.
Attendees will also receive practical guidance to streamline workflows, optimize testing from cell bank to release and advance ADC programs with confidence. Expect insights that enable sharper decision-making, stronger data and faster regulatory preparation.
Agenda
- Overview of ADCs and key development considerations
- Accelerating cell banking testing for critical ADC intermediates
- Analytical characterization and testing strategies for ADCs
- End-to-end workflow – from cell bank characterization to final batch release
Target audience
The webinar is aimed at biopharma and pharma professionals, including those working on biologics and antibody-based therapeutics, upstream and downstream process scientists, analytical development scientists, chemistry, manufacturing and controls (CMC) specialists and quality control/quality assurance (QC/QA) personnel.
This event takes place on April 28, 2026, at 03:00 pm CET.
